Replies to post #208861 on Biotech Values

[zipjet]

[GILD} shouldn't have spent their profits on Buybacks, Dividends etc but rather they should have acquired top echelon assets.

And GILD could have done that when their stock was peaking using both the CF and stock.

PE's are sensitive to the life of the CF's, if the life is not long or going to be reinvested in assets with similar ROE then the market will drop the PE.

[willyw]

is fantastic for the Patient, but not so for the Producer.

Ha!! Tell that to John Martin.

Look at what Gilead spent on Pharmasett (11 billion for a drug in Phase 3) and what they will net after a decade of treatments.
There may be a small silver lining for Gilead in this tragedy.

Look at what happened to Incivek; they had about 2 years before warehousing started. I think Gilead will have an extended period of income. China hasn't really even started yet. The prospects for Abbvie and G/P still look good to me as well.